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Peramivir, the only injectable anti-inﬂuenza neuraminidase inhibitor medically available in Japan at
present, is considered ﬁrst-line treatment in patients with high risk factors for inﬂuenza exacerbation.
We conducted a drug-use investigation of peramivir in inpatients with high risk factors (old age, preg-
nancy, and underlying disease such as chronic respiratory disease) from January 2010 to March 2013.
Data of 772 patients from 124 facilities across Japanwere collected; peramivir's safety in 770 patients and
effectiveness in 688 patients were examined. In total, 412 adverse events were observed in 219 patients
(28.4%). Of these, 155 events were adverse drug reactions (ADRs) observed in 98 patients (12.7%). Major
ADRs (2%) were increased aspartate aminotransferase (5.1%), increased alanine aminotransferase (3.8%)
and decreased white blood cell count (2.5%). Fourteen serious ADRs were observed in 12 patients (1.6%).
All serious ADRs were resolved or improved except for two events for which outcomes were unknown.
Multivariate analyses revealed that ADR incidences were signiﬁcantly associated with these four back-
grounds of patients: medical history, no inﬂuenza vaccination, renal impairment and other infection(s).
With regard to its effectiveness, the median time to alleviation of both inﬂuenza symptoms and fever was
3 days, including the ﬁrst day of administration, which was the same as in other previous surveillance
studies. This surveillance study indicated the safety of peramivir in the treatment of inﬂuenza inpatients
with high risk factors under routine clinical settings.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Japanese Society of Chemotherapy and
The JapaneseAssociation for InfectiousDiseases. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent meta-analysis results have shown that treatment with
anti-inﬂuenza neuraminidase inhibitor (NAI) at early disease stage
(within 2 days of symptom onset) to inpatients infected by
inﬂuenza A H1N1pdm09 virus results in signiﬁcant reduction of
mortality [1]. From these ﬁndings, early interventionwith NAI can
be expected to exert important efﬁcacy in patients who require
hospitalized care and may develop inﬂuenza exacerbation due to
high risk factors (old age, pregnancy, and underlying disease such
as chronic respiratory disease). At present, four NAIs are medicallyomeda).
on behalf of Japanese Society of Chem
org/licenses/by-nc-nd/4.0/).available in Japan (oseltamivir, zanamivir, peramivir and lanina-
mivir). Of these, peramivir is the only injectable drug; reliable
transfer of active ingredients during intravenous infusion should
exhibit efﬁcacy. Thus, peramivir is considered ﬁrst-line treatment
in patients with high risk factors who are given high dosage or
administered repeatedly [2], although it is usually given as a
single dose in patients whose disease conditions are relatively
mild.
In fact, the efﬁcacy/effectiveness and safety of peramivir has
been reported from clinical trials [2e5] and post-marketing sur-
veillance studies [6,7]; however, the outcome information on in-
patients with high risk factors, if any, has been obtained from a
limited number of patients as many were outpatients. Therefore,
the efﬁcacy and safety information of peramivir from clinicalotherapyand The Japanese Association for Infectious Diseases. This is anopen access article
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vention in inpatients with high risk factors.
We conducted a drug-use investigation of peramivir in in-
patients with high risk factors from January 2010 to March 2013.
This was required as a condition for approval by the Japanese
Ministry of Health, Labour and Welfare (MHLW) and was con-
ducted in compliance with the Good Post-Marketing Study Prac-
tice speciﬁed by the MHLW Ordinance No. 171 (December 20,
2004).
This paper focuses on the results from an observational drug-
use investigation performed in inpatients with high risk factors
under routine clinical settings for the purpose of evaluating safety
and effectiveness proﬁles of peramivir.
2. Patients and methods
2.1. Patients
We deﬁned the target population as inpatients with inﬂuenza
infection possessing high risk factors and surveyed them from 124
facilities during the period of January 2010 to March 2013. Patients
with high risk factors were deﬁned as those with at least one of the
following characteristics: being pregnant, being65 years old, and
suffering from an underlying disease/complication that might
exacerbate inﬂuenza infection such as chronic respiratory illness/
heart disease/kidney disease/liver disease, neurological/neuro-
muscular disorder, blood dyscrasia, diabetes mellitus, and immu-
nosuppression associated with disease or therapy.
2.2. Dosage and administration
The standard dose of peramivir is 300 or 600 mg/day for adult
and 10 mg/kg/day, not to exceed 600 mg at a time, for children,
given as an I.V. infusion for 15 min, respectively.
2.3. Surveillance study procedure
This surveillance study was implemented in the manner of a
continuous investigation system, wherein the participating phy-
sicians were instructed to continuously complete survey forms of
patients who were judged by the participating physicians as
matching the target population described in “2.1. Patients”without
exception until the patient number reached the requested quota
(including retrospective cases). The physicians completed the
survey forms, including baseline characteristics of the patients and
the items related to adverse events (AEs) and effectiveness. Noting
the presence/absence of the following AEs was required to ensure
their detection: abnormal behavior, leukopenia/neutropenia,
eosinophilia, diarrhea, nausea/vomiting, elevated aspartate
aminotransferase (AST)/alanine aminotransferase (ALT), positive
urine ketone bodies, anaphylactic symptoms, and psychiatric/
neurological symptoms.
2.4. Safety evaluation criteria
AEs were deﬁned as any unfavorable/unintended sign tempo-
rally associated with peramivir administration, whether or not
considered related to peramivir. Adverse drug reactions (ADRs)
were deﬁned as AEs for which the causality of peramivir could not
be ruled out as determined by the participating physicians or
sponsor. Seriousness of AEs/ADRs was determined in accordance
with the deﬁnition in the ICH-E2D guideline. ADR data were
compiled according to the ICH Medical Dictionary for Regulatory
Activities/J (Ver.16.1).2.5. Effectiveness evaluation criteria
Effectiveness was evaluated as the time to alleviation of inﬂu-
enza symptoms and fever. The severity of inﬂuenza symptoms,
including cough, sore throat, headache, nasal congestion, feverish
feeling or chills, muscle or joint pain, and fatigue, were evaluated
on a four-point scale as follows: normal condition, barely notice-
able, bothersome, and unbearable. Symptom alleviation was
considered to have occurred when all observed symptoms were
scored “barely noticeable” or better. Fever alleviation was consid-
ered to have occurred when a maximum daily body temperature of
<37 C in adults (age 15 years) or <37.5 C in children (age <15
years) was reached. And the time to symptom/fever alleviationwas
deﬁned as the number of days from the start of peramivir admin-
istration to these endpoints.
2.6. Statistical analysis
The chi-square test was used to compare incidence rates of ADRs
between categories of patient characteristics and treatment factors.
For ordinal variables for which the chi-square test detected sig-
niﬁcant differences, the CochraneArmitage test for trend was used.
To assess whether the observed differences were proportional to
the category order, the goodness of ﬁt test was used. The factors
showing signiﬁcance in univariate analysis were further assessed as
explanatory variables of a logistic regression model to determine
themajor factor(s) in ADRs. The response “unknown”was excluded
from the data analysis. Effectiveness was assessed by ﬁrst calcu-
lating the median time (days) to alleviation of inﬂuenza symptoms
and fever and then obtaining KaplaneMeier curves showing the
time course of the proportion of patients remaining symptomatic. A
two-sided signiﬁcance level of 5% was used throughout. All of the
various data analyses were performed using the SAS system
(release 9.2).
3. Results
3.1. Baseline patient characteristics
We collected data of 772 patients from 124 facilities and
examined safety in 770 patients and effectiveness in 688 patients
(Fig. 1).
A total of 770 patients were analyzed for safety (Table 1),
including one pregnant woman, 463 elderly (65 years) patients
(60.1%), and 765 inpatients (99.4%). Inﬂuenza A and B accounted for
663 patients (86.1%) and 82 patients (10.6%), respectively. Among
the 770 patients analyzed for safety, 617 patients (80.1%) possessed
at least one of underlying diseases/complications classiﬁable as high
risk factors. These underlying diseases/complications were classi-
ﬁed into each high risk factor as follows: chronic respiratory disease
(354 patients), immunosuppression associated with disease or
therapy (348 patients), neurological disorders/neuromuscular dis-
orders (158 patients), chronic heart disease (143 patients), diabetes
mellitus (110 patients), chronic kidney disease (48 patients), chronic
liver disease (12 patients) and blood dyscrasias (7 patients).
3.2. Safety
3.2.1. ADR incidence and type
In total, 412 AEs occurred in 219 (28.4%) of the 770 patients. AEs
with an incidence of 3% were increased AST (9.2%), increased ALT
(7.7%), and decreased white blood cell count (4.2%). One hundred
twenty-ﬁve serious AEs occurred in 77 patients (10.0%). Serious AEs
with an incidence of 1% were decreased neutrophil count (1.4%),
pneumonia (1.4%), increased AST (1.3%), decreased white blood cell
Number of patients whose 
data were collected
772 patients
Number of patients excluded from 
safety analysis
2 patients
Duplicate cases 1 patient
Not observed after the initiation 
of treatment
1 patient
Safety analysis set
770 patients
Number of patients excluded from 
effectiveness analysis
82 patients
2 patientsNot observed after treatment
Not meeting the criteria for the
target population1)
80 patients
Effectiveness analysis set
688 patients
Patients excluded from the 
analysis of the time to 
alleviation of fever
108
patients
Patients excluded from the analysis of 
the time to alleviation of influenza 
symptoms
187
patients
Normal body 
temperature/unknown at 
baseline2)
106
patients
Low severity/unknown at baseline3) 183
patients
Not observed after
treatment
3 patients Not observed after treatment 25 patients
(more than one reason for exclusion) (more than one reason for exclusion)
Time to alleviation of 
fever analysis set
Time to alleviation of influenza 
symptoms analysis set
580 patients 501 patients
1) Patients who did not meet the criteria for the target population as described in “2.1 Patients” for reasons such as influenza virus 
undetected/unknown
2) Patients whose body temperatures were <37°C (<37.5°C in case of children aged <15 years) or unknown at baseline.
3) Patients whose severity of all influenza symptoms (cough, sore throat, headache, nasal congestion, feverish feeling or chills, muscle or joint 
pain, and fatigue) at baseline were either absent to mild or unknown, as assessed on a four-point scale [absent (normal condition), 
mild (barely noticeable), moderate (bothersome), and severe (unbearable)].
Fig. 1. Patient composition.
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count (1.0%). Of the 412 AEs, 155 were reported as ADRs, and they
occurred in 98 patients (12.7%; Table 2). Major ADRs (2%)
were increased AST (5.1%), increased ALT (3.8%), and decreased
white blood cell count (2.5%). Regarding the major ADRs and
other related ADRs, 80 events of abnormal liver function test-
related ADRs occurred in 55 patients (7.1%), and 26 events of
leukopenia/neutropenia-related ADRs occurred in 23 patients
(3.0%) (Table 3A). Fourteen serious ADRs occurred in 12 patients
(1.6%), which included 5 cases of decreased white blood cell count,
4 cases of decreased neutrophil count, 2 cases of increased blood
creatine phosphokinase, and 1 case each of viral myositis, rhab-
domyolysis and increased AST.
3.2.2. Onset time and duration of ADRs
Most of themajor ADRs and other related ADRswere resolved or
improved within a week of onset (Table 3A). Regarding seriousADRs, apart from 2 events with unknown outcomes, all resolved or
improved and there were no cases with serious outcomes of death
or sequelae (Table 3B).3.2.3. Risk factors for ADR occurrence
Table 4 shows ADR incidence by background factor. From the
chi-square test, patients with “medical history present”, “no inﬂu-
enza vaccination”, “renal impairment present” and “other in-
fection(s) present” were seen to have signiﬁcantly higher ADR
incidence. Signiﬁcant differences were also observed between age
categories. There were no signiﬁcant differences between cate-
gories in terms of dose or duration of peramivir administered.
Multivariate analysis results (Table 5) revealed that ADR incidences
were signiﬁcantly associated with these four backgrounds of pa-
tients: medical history, no inﬂuenza vaccination, renal impairment
and other infection(s).
Table 1
Distribution of baseline characteristics.
Parameter Category Number
of
patients
Composition
(%)
All patients 770 100.0
Gender Male 404 52.5
Female 366 47.5
Age <15 years 181 23.5
15 years to <65 years 125 16.2
65 years 463 60.1
Unknown 1 0.1
Mean ± S.D. (years) 58.0 ± 32.2
Minimum (years) 0
Median (years) 73.0
Maximum (years) 103
Body weight <30 kg 155 20.1
30 kg to <40 kg 89 11.6
40 kg to <50 kg 128 16.6
50 kg to <60 kg 133 17.3
60 kg to <70 kg 91 11.8
70 kg 49 6.4
Unknown 125 16.2
Mean ± S.D. (kg) 44.00 ± 19.40
Minimum (kg) 4.6
Median (kg) 46.10
Maximum (kg) 110.0
Pregnancy (women
only)
No 365 99.7
Yes 1 0.3
Nursing (women only) No 366 100.0
Yes 0 0.0
Time (days) from the
onset of inﬂuenza to
the initiation of
peramivir
administration
0 day 317 41.2
1 day 263 34.2
2 day 90 11.7
3 days 97 12.6
Unknown 3 0.4
Virus type (test results
using rapid
diagnostic kits)
Type A 663 86.1
Type B 82 10.6
Others 10 1.3
Unknown 15 1.9
Type A (at onset) 2009e2010 9 1.4
2010e2011 225 33.9
2011e2012 248 37.4
2012e2013 181 27.3
Inpatient/outpatient Inpatient 765 99.4
Outpatient 5 0.6
Currently smoking No 678 88.1
Yes 59 7.7
Unknown 33 4.3
Inﬂuenza vaccine No 347 45.1
Yes 228 29.6
Unknown 195 25.3
Severity at baselinea
(baseline score)
7 349 45.3
8e14 228 29.6
15 38 4.9
Unknown 155 20.1
Medical historyb No 646 83.9
Yes 124 16.1
Underlying diseases/
complications
No 17 2.2
Yes 753 97.8
Hepatic impairment No 725 94.2
Yes 45 5.8
Renal impairment No 710 92.2
Yes 60 7.8
High risk factorsc
(underlying disease)
No 153 19.9
Yes 617 80.1
Other infection(s) No 495 64.3
Yes 275 35.7
Allergies No 593 77.0
Yes 86 11.2
Unknown 91 11.8
Highest daily body
temperature (before
the initiation of
treatment with
peramivir)
<38 C 158 20.5
38 C to <40 C 479 62.2
40 C 51 6.6
Unknown 82 10.6
Table 1 (continued )
Parameter Category Number
of
patients
Composition
(%)
Serious inﬂuenzad No 650 84.4
Yes 49 6.4
Unknown 71 9.2
Daily dose (maximum) <300 mg 199 25.8
300 mg to <600 mg 482 62.6
600 mg to <1200 mg 88 11.4
1200 mg 1 0.1
Number of times dosed
daily (most often)
1 time 752 97.7
2 times 17 2.2
Unknown 1 0.1
Duration of treatment 1 day 577 74.9
2 days 122 15.8
3 days 46 6.0
4 days 11 1.4
5 days 14 1.8
Total dose <300 mg 168 21.8
300 mg to <600 mg 400 51.9
600 mg to <1200 mg 154 20.0
1200 mg 48 6.2
Concomitant drugs No 46 6.0
Yes 723 93.9
Unknown 1 0.1
a Total of scores [0: absent (normal condition); 1: mild (barely noticeable); 2:
moderate (bothersome); 3: severe (unbearable)] for each inﬂuenza symptom
(cough, sore throat, headache, nasal congestion, feverish feeling or chills,
muscle or joint pain, and fatigue) at baseline. Cases with even one missing (not
described, unknown) score for any of the seven symptoms were handled as
“unknown”.
b Diseases/symptoms that were previously developed and recovered prior to
peramivir administration.
c Underlying diseases/complications that may exacerbate inﬂuenza infections,
such as chronic respiratory illness, chronic heart disease, chronic kidney disease,
chronic liver disease, neurological disorders/neuromuscular disorders, blood
dyscrasia, diabetes mellitus, and immunosuppression associated with disease or
therapy.
d Patients who had inﬂuenza encephalopathy or who were on mechanical
ventilation at baseline.
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ADR incidence, the following results were obtained. The incidence
of “Investigations”was signiﬁcantly higher (p¼ 0.0233) in patients
who had not received inﬂuenza vaccine (37/347, 10.7%) than those
who had (12/228, 5.3%). The leukopenia/neutropenia-related ADR
incidence was signiﬁcantly higher (p ¼ 0.0023) in patients with
medical history (9/124, 7.3%) than those without (14/646, 2.2%).
The incidence of abnormal liver function test-related ADRs was
signiﬁcantly higher (p < 0.0001) in patients with other infections
(33/275, 12.0%) than in those without (22/495, 4.4%). In the renal
impairment patients, the ADR incidence of “gastrointestinal dis-
orders” was signiﬁcantly higher (<0.0001) (5/60, 8.3%) compared
with patients without renal impairment (6/710, 0.8%). Especially,
the incidence of “diarrhea” was higher in patients with renal
impairment (3/60, 5.0%) than in those without (6/710, 0.8%).
However, the cases of diarrhea that occurred in renal impairment
patients were non-serious and resolved or improved by the day
after onset.3.3. Effectiveness
Fig. 2 shows KaplaneMeier curves for the time (days) to alle-
viation of inﬂuenza symptoms and fever. The median time to
alleviation of both inﬂuenza symptoms and fever was 3 days
(including the ﬁrst day of peramivir administration), and
improvement was observed within 3 days in 69.4% (344/496) and
62.4% (358/574) of patients with inﬂuenza symptoms and fever,
respectively.
Table 2
Incidence rates of adverse drug reactions (ADRs).
Number of patients evaluated for safety 770
Number of patients with ADRs 98
Number of ADRs 155
Incidence of ADRs 12.7%
Type of ADR Incidence of
ADRs [number (%)]
Infections and infestations 1 (0.1)
Viral myositis 1 (0.1)
Metabolism and nutrition disorders 1 (0.1)
Hypokalaemia 1 (0.1)
Psychiatric disorders 3 (0.4)
Abnormal behaviour 3 (0.4)
Gastrointestinal disorders 11 (1.4)
Constipation 1 (0.1)
Diarrhea 9 (1.2)
Nausea 1 (0.1)
Vomiting 1 (0.1)
Hepatobiliary disorders 10 (1.3)
Hepatic function abnormal 7 (0.9)
Liver disorder 3 (0.4)
Skin and subcutaneous tissue disorders 2 (0.3)
Rash 2 (0.3)
Musculoskeletal and connective tissue disorders 2 (0.3)
Arthralgia 1 (0.1)
Rhabdomyolysis 1 (0.1)
General disorders and administration site conditions 3 (0.4)
Hyperthermia 1 (0.1)
Pyrexia 2 (0.3)
Investigations 75 (9.7)
Alanine aminotransferase increased 29 (3.8)
Aspartate aminotransferase increased 39 (5.1)
Blood creatine phosphokinase increased 4 (0.5)
Blood creatinine increased 1 (0.1)
Blood lactate dehydrogenase increased 1 (0.1)
Eosinophil count increased 10 (1.3)
Gamma-glutamyltransferase increased 1 (0.1)
Neutrophil count decreased 7 (0.9)
White blood cell count decreased 19 (2.5)
Urine ketone body present 8 (1.0)
Hepatic enzyme increased 2 (0.3)
Incidence of ADRs (%) ¼ number of patients with ADRs (events)/total number of
patients evaluated for safety 100.
Types of ADRs are shown using terms from MedDRA/J Ver.16.1.
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In this surveillance study, evaluation of 770 patients for safety
and 688 patients for effectiveness of peramivir use under routine
clinical settings was performed. Most of the patients evaluated forTable 3A
Time of onset, outcome, and time until “resolved or improved” by type of major ADRs a
Type of ADR Number
of
events
Time of onset Outcom
1 to 3
days
4 to 7
days
8
days
Resolv
Abnormal liver
function tests related ADRs
Aspartate
aminotransferase
increased
39 25 12 2 25
Alanine
aminotransferase
increased
29 12 14 3 21
Hepatic function
abnormal
7 4 2 1 5
Liver disorder 3 2 1 3
Hepatic enzyme
increased
2 1 1 1
Leukopenia/neutropenia
related ADRs
White blood cell
count decreased
19 9 10 15
Neutrophil count
decreased
7 2 5 6safety were inpatients and >60% were elderly patients and 80%
possessed underlying diseases/complications classiﬁable as high
risk factors. Further, a major proportion of the underlying diseases/
complications classiﬁable as high risk factors were chronic respi-
ratory disease and immunosuppression associated with disease or
therapy.
The ADR incidence (12.7%) was higher than those in a previous
surveillance study (4.4%) [6] and in a pediatric surveillance study
(7.7%) [7]. As one of the possible explanations for the high ADR
incidence, it is likely that abnormal signs were more easily
detected in this surveillance study than in the other surveillance
studies. Although approximately 90% of patients were outpatients
in the other surveillance studies, most patients were inpatients
and a large number of patients had underlying diseases/compli-
cations in this surveillance study. Thus, it seems that the patients
received more careful inspection and this made abnormal signs
more easily detected in this surveillance study. Indeed, the high
ADR incidence was due to the increase of laboratory test-related
ADRs; this supports the above explanation. Of course, as another
possible explanation, it could be considered that the severity of the
patient's condition inﬂuenced the ADR incidence.
Regarding the major ADRs of abnormal liver function
test-related and leukopenia/neutropenia-related events in this
surveillance study, these ADRs are known to occur in a proportion
of inpatients with inﬂuenza [8]. Furthermore, there are some re-
ports suggesting that treatment with NAIs was not associated with
hepatotoxicity or neutropenia [9,10]. Taken together, it is possible
that these ADRs were related with the infection of inﬂuenza itself.
Serious ADRs observed in this surveillance study were
leukopenia/neutropenia-related events (decreased white blood cell
count, decreased neutrophil count), muscular-related events
(increased blood creatine phosphokinase, viral myositis, rhabdo-
myolysis) and abnormal liver function test-related events
(increased AST). All of these ADRs appear to be consequences of
inﬂuenza infection because muscular-related events are also well
known to be caused by inﬂuenza infection itself, although the
causal relationship between peramivir and these ADRs could not be
denied, of course. Among patients with serious ADRs, most of them
were resolved or improved within two weeks and there were no
cases with a problematic outcome such as death or sequelae.
From the results of multivariate analysis, four factors such as
other infection(s), medical history, no inﬂuenza vaccination and
renal impairment were suggested to be signiﬁcantly related to the
occurrence of ADRs. Regarding patients with other infections,nd other related ADRs.
e Time until resolved or improved
ed Improved Not
resolved
Resolved
but with
sequela
Death Unknown 0 to 3
days
4 to 7
days
8 to 14
days
15
days
8 1 5 12 11 8 2
5 3 5 11 7 3
2 2 1 2
1 1 1
1 1
2 2 5 5 4 3
1 2 2 2 1
Table 3B
Time of onset, outcome, and time until “resolved or improved” by type of serious ADRs.
Type of ADR Number
of serious
events
Time of onset Outcome Time until resolved or improved
1 to 3
days
4 to 7
days
8
days
Resolved Improved Not
resolved
Resolved but
with sequela
Death Unknown 0 to 3
days
4 to 7
days
8 to 14
days
15 days
White blood cell count decreased 5 5 4 1 1 2 1
Neutrophil count decreased 4 1 3 3 1 1 1 1 1
Blood creatine phosphokinase increased 2 1 1 1 1 1
Viral myositis 1 1 1 1
Rhabdomyolysis 1 1 1 1
Aspartate aminotransferase increased 1 1 1 1
Table 4
Risk factors for the occurrence of ADRs.
Parameter Category Incidence of
ADRs (%)
p value
All patients 12.7 (98/770) e
Gender Male 12.1 (49/404) p1 ¼ 0.6006
Female 13.4 (49/366)
Age <15 years 7.2 (13/181) p1 ¼ 0.0396*
15 years to <65
years
15.2 (19/125) p2 ¼ 0.0333*
65 years 14.0 (65/463) p3 ¼ 0.1652
Unknown 100.0 (1/1)
Body weight <30 kg 9.0 (14/155) p1 ¼ 0.1653
30 kg to <40 kg 16.9 (15/89)
40 kg to <50 kg 14.8 (19/128)
50 kg to <60 kg 7.5 (10/133)
60 kg to <70 kg 15.4 (14/91)
70 kg 14.3 (7/49)
Unknown 15.2 (19/125)
Pregnancy (women
only)
No 13.4 (49/365) p1 ¼ 0.6938
Yes 0.0 (0/1)
Nursing (women only) No 13.4 (49/366) e
Yes e
Time (days) from the
onset of inﬂuenza to
the initiation of
peramivir
administration
0 day 10.4 (33/317) p1 ¼ 0.1908
1 day 16.0 (42/263)
2 days 14.4 (13/90)
3 days 10.3 (10/97)
Unknown 0.0 (0/3)
Virus type (test results
using rapid
diagnostic kits)
Type A 13.7 (91/663) p1 ¼ 0.1968
Type B 8.5 (7/82)
Others 0.0 (0/10)
Unknown 0.0 (0/15)
Type A (at onset) 2009e2010 22.2 (2/9) p1 ¼ 0.7155
2010e2011 13.3 (30/225)
2011e2012 12.5 (31/248)
2012e2013 15.5 (28/181)
Inpatient/outpatient Inpatient 12.7 (97/765) p1 ¼ 0.6245
Outpatient 20.0 (1/5)
Currently smoking No 12.1 (82/678) p1 ¼ 0.1462
Yes 18.6 (11/59)
Unknown 15.2 (5/33)
Inﬂuenza vaccine No 13.5 (47/347) p1 ¼ 0.0142*
Yes 7.0 (16/228)
Unknown 17.9 (35/195)
Severity at baseline
(baseline score)
7 11.5 (40/349) p1 ¼ 0.2322
8e14 13.2 (30/228)
15 21.1 (8/38)
Unknown 12.9 (20/155)
Medical history No 11.6 (75/646) p1 ¼ 0.0337*
Yes 18.5 (23/124)
Underlying disease/
complications
No 5.9 (1/17) p1 ¼ 0.3918
Yes 12.9 (97/753)
Hepatic impairment No 12.6 (91/725) p1 ¼ 0.5574
Yes 15.6 (7/45)
Renal impairment No 11.8 (84/710) p1 ¼ 0.0103*
Yes 23.3 (14/60)
High risk factors
(underlying disease)
No 9.8 (15/153) p1 ¼ 0.2255
Yes 13.5 (83/617)
Other infection(s) No 10.1 (50/495) p1 ¼ 0.0033*
Yes 17.5 (48/275)
Allergies No 12.3 (73/593) p1 ¼ 0.2622
Yes 8.1 (7/86)
Unknown 19.8 (18/91)
Table 4 (continued )
Parameter Category Incidence of
ADRs (%)
p value
Highest daily body
temperature (before
the start of
treatment with
peramivir)
<38 C 12.7 (20/158) p1 ¼ 0.9554
38 C to <40 C 13.6 (65/479)
40 C 13.7 (7/51)
Unknown 7.3 (6/82)
Serious inﬂuenza No 13.2 (86/650) p1 ¼ 0.8339
Yes 14.3 (7/49)
Unknown 7.0 (5/71)
Daily dose (maximum) <300 mg 10.6 (21/199) p1 ¼ 0.2151
300 mg to
<600 mg
12.4 (60/482)
600 mg to
<1200 mg
19.3 (17/88)
1200 mg 0.0 (0/1)
Number of times dosed
daily (most often)
1 time 12.9 (97/752) p1 ¼ 0.3909
2 times 5.9 (1/17)
Unknown 0.0 (0/1)
Duration of treatment 1 day 12.5 (72/577) p1 ¼ 0.5156
2 days 11.5 (14/122)
3 day 13.0 (6/46)
4 days 27.3 (3/11)
5 days 21.4 (3/14)
Total dose <300 mg 9.5 (16/168) p1 ¼ 0.1235
300 mg to
<600 mg
11.8 (47/400)
600 mg to
<1200 mg
17.5 (27/154)
1200 mg 16.7 (8/48)
Concomitant drugs No 8.7 (4/46) p1 ¼ 0.3958
Yes 13.0 (94/723)
Unknown 0.0 (0/1)
Incidence of ADRs (%) ¼ number of patients with ADR/total number of patients
evaluated for safety  100.
*: p < 0.05.
p1: c2 test, p2: CochraneArmitage test, p3: Goodness of ﬁt.
T. Komeda et al. / J Infect Chemother 22 (2016) 677e684682since abnormal liver function test-related ADRs occurred with
high frequency, detailed examination of the type of other in-
fection(s) in 33 abnormal liver function test-related ADR cases was
performed. Of the 33 ADR cases, 32 cases had pneumonia/bron-
chitis and the remaining 1 case had bacteraemia. It was considered
that an exacerbated physical condition due to pneumonia/
bronchitis and/or drugs such as antibiotics for treatment of these
infections could possibly have an inﬂuence on the liver function
test values. As the incidence of leukopenia/neutropenia-related
ADRs was found to be high in patients with medical history, the
medical history of 9 leukopenia/neutropenia-related ADR cases
was examined in detail. However, no common disease was
observed in these 9 cases.
Unlike patients in relatively good condition, the administration
of peramivir in high doses and/or in a repeated manner would
likely occur in inpatients with high risk factors. Indeed, 88 patients
were administered 600 mg and 193 patients were given repeated
doses. However, the categories of peramivir dose or duration of
Table 5
Multivariate analysis to ﬁnd risk factors.
Parameter Category Number of
evaluated patients
Number of
patients with ADRs
Incidence of
ADRs (%)
Estimate Standard
error
Odds ratio
(95% CI)
p value
Analysis set 574 62 10.8
Intercept 3.201 0.451 <0.0001*
Age <15 years 131 6 4.6 e e e e
15 years to <65 years 102 15 14.7 1.003 0.514 2.726 (0.996, 7.461) 0.0508
65 years 341 41 12.0 0.694 0.463 2.002 (0.808, 4.959) 0.1336
Inﬂuenza vaccine No 346 46 13.3 e e e e
Yes 228 16 7.0 0.685 0.313 0.504 (0.273, 0.931) 0.0286*
Medical history No 488 45 9.2 e e e e
Yes 86 17 19.8 0.885 0.331 2.423 (1.267, 4.636) 0.0075*
Other infection(s) No 391 30 7.7 e e e e
Yes 183 32 17.5 0.979 0.284 2.663 (1.527, 4.643) 0.0006*
Renal impairment No 530 52 9.8 e e e e
Yes 44 10 22.7 0.900 0.409 2.459 (1.104, 5.475) 0.0277*
CI, conﬁdence interval.
*p < 0.05.
Fig. 2. KaplaneMeier curves of time to alleviation of inﬂuenza symptoms and of fever.
T. Komeda et al. / J Infect Chemother 22 (2016) 677e684 683administration were not observed to be factors related to ADR
incidence in this surveillance study.
With regard to the effectiveness, the median number of days to
fever alleviation and inﬂuenza symptom alleviation was 3 days,
which was similar to that found in other previous surveillance
studies [6,7], although the observation conditions of patients are
thought to differ.
This surveillance study has some limitations. It could not be
denied that the surveillance study procedure might introduce bias
into the safety evaluation because this surveillance study was
conducted in an open-labeled manner and the participating phy-
sicians could determine AEs as ADRs. Actually, some AEs supposed
to be caused by inﬂuenza infection itself were included in the
ADRs. On the other hand, the incidence of laboratory test-related
ADR might be underestimated. Because, in this surveillance
study, laboratory tests were measured as needed under routine
clinical settings and it was not conﬁrmed whether each laboratory
test was measured or not, the exact number of patients whose
laboratory tests were measured could not be determined. Thus,
applying all of the 770 patients to the denominator for calculation
of the laboratory test-related ADR incidence might make theestimation of the incidence lower. However, taking into consid-
eration that most patients were inpatients in this surveillance, it
was supposed that laboratory tests were measured in most pa-
tients and the degree of lower estimation was small, if any.
Regarding effectiveness evaluation, the efﬁcacy of peramivir could
not be clearly demonstrated because this surveillance study was
conducted without control. However, taking the fact that the
median time to alleviation of both inﬂuenza symptoms and fever
was 3 days which was consistent with previous surveillance
studies [6,7] into consideration, it is suggested that the peramivir
was effective even in patients with high risk factors.
This surveillance study indicated the safety of peramivir in the
treatment of inﬂuenza inpatients with high risk factors under
routine clinical settings and this surveillance study would support
the implementation of proper use of peramivir in patients with
high risk factors.Conﬂict of interest
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